Patents by Inventor Robert Z. Orlowski

Robert Z. Orlowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES TARGETING HSP70 AND THERAPEUTIC USES THEREOF
    Publication number: 20230128075
    Abstract: Provided herein are agents, such as antibodies and chimeric antigen receptors, that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicants: Board of Regents, The University of Texas System, Asylia Therapeutics
    Inventors: Robert Z. ORLOWSKI, Richard J. JONES, Laura C. BOVER, Jeno GYURIS, John MILLER, James Bernard McCLORY, Darragh MAC CANN, William M. WINSTON, SR.
  • Potent and specific immunoproteasome inhibitors
    Patent number: 7589066
    Abstract: Compounds and methods of selectively inhibiting an immunoproteasome are described. Also described are methods of treating a cancer, an inflammation, and/or an autoimmune disease and methods of suppressing endogenous antigenic peptide generation by administering to a subject in need of treatment thereof a therapeutic amount of an immunoproteasome specific inhibitor.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: September 15, 2009
    Assignees: The University of North Carolina at Chapel Hill, Mount Sinai School of Medicine of New York University
    Inventors: Robert Z. Orlowski, Marian Orlowski
  • METHOD OF USING IL6 ANTAGONISTS WITH PROTEASOME INHIBITORS
    Publication number: 20090022726
    Abstract: The invention is directed to a method of treating a cancerous disorder or condition, or an IL-6related disorder or condition, in a mammal in need of such treatment, which comprises co-administering a proteasome inhibitor in combination with an IL-6antagonist
    Type: Application
    Filed: December 8, 2006
    Publication date: January 22, 2009
    Inventors: Mohamed Zaki, Jeffrey Nemeth, Robert Z. Orlowski